We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ademi & O'Reilly, LLP announced that it filed a class action lawsuit on behalf of purchasers of Par Pharmaceutical Companies Inc. (``Par'' or the ``Company'') securities during the period between April 29, 2004, and July 5, 2006 (the ``Class Period'').
Shares of DOV Pharmaceutical Inc. slipped to a fresh 52-week low after the biopharmaceutical company said it received a letter from the Nasdaq that it failed to comply with several listing requirements.
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), released a statement encouraging the U.S. Senate to swiftly confirm Dr. Andrew von Eschenbach as commissioner of the Food and Drug Administration (FDA).
A U.S. senator has called for a probe of the U.S. Food and Drug Administration, saying the agency gave preferential treatment to Vioxx marketer Merck & Co. Senate Finance Chairman Charles Grassley, R-Iowa, says the FDA gave Merck notice before it let the public know that the popular pain drug was tied to increased risks of heart attack and stroke, CBS News reported.
Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc., announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market a generic version of Pfizer Inc.'s XANAX XR (Alprazolam Extended-Release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg.
The FDA, in a move that mirrors a promise the agency made during former Commissioner Lester Crawford's nomination hearing, is pledging to decide within weeks whether to allow OTC sales of the controversial contraceptive Plan B.